Cancer patients get continued access to lifesaving drug in new study

NCT ID NCT05629234

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the drug will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Research Site

Beijing, 100142, China
Research Site

Chongqing, 400042, China
Research Site

Yangzhou, 225001, China
Research Site

Zhengzhou, 450008, China
Research Site

Villejuif, 94805, France
Research Site

Kashiwa, 277-8577, Japan
Research Site

George Town, 10450, Malaysia
Research Site

Johor Bahru, 81100, Malaysia
Research Site

Kuantan, 25100, Malaysia
Research Site

Kuching, 93586, Malaysia
Research Site

Szczecin, 70-419, Poland
Research Site

Cheongju-si, 28644, South Korea
Research Site

Donggu, 44033, South Korea
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Seoul, 5505, South Korea
Research Site

Kaohsiung City, 83301, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 704, Taiwan
Research Site

Tainan, 736, Taiwan
Research Site

Taipei, 112201, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Nottingham, NG5 1PB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.